CA3099338A1 - Methods and compositions for treating chronic urticaria - Google Patents

Methods and compositions for treating chronic urticaria Download PDF

Info

Publication number
CA3099338A1
CA3099338A1 CA3099338A CA3099338A CA3099338A1 CA 3099338 A1 CA3099338 A1 CA 3099338A1 CA 3099338 A CA3099338 A CA 3099338A CA 3099338 A CA3099338 A CA 3099338A CA 3099338 A1 CA3099338 A1 CA 3099338A1
Authority
CA
Canada
Prior art keywords
seq
antibody
amino acid
acid sequence
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099338A
Other languages
English (en)
French (fr)
Inventor
Christopher Robert Bebbington
Nenad Tomasevic
Henrik Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allakos Inc
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of CA3099338A1 publication Critical patent/CA3099338A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3099338A 2018-05-04 2019-05-03 Methods and compositions for treating chronic urticaria Pending CA3099338A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862667242P 2018-05-04 2018-05-04
US62/667,242 2018-05-04
US201962788719P 2019-01-04 2019-01-04
US62/788,719 2019-01-04
US201962797817P 2019-01-28 2019-01-28
US62/797,817 2019-01-28
US201962803211P 2019-02-08 2019-02-08
US62/803,211 2019-02-08
US201962806657P 2019-02-15 2019-02-15
US62/806,657 2019-02-15
PCT/US2019/030523 WO2019213468A1 (en) 2018-05-04 2019-05-03 Methods and compositions for treating chronic urticaria

Publications (1)

Publication Number Publication Date
CA3099338A1 true CA3099338A1 (en) 2019-11-07

Family

ID=68386174

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099338A Pending CA3099338A1 (en) 2018-05-04 2019-05-03 Methods and compositions for treating chronic urticaria

Country Status (11)

Country Link
US (1) US20210246205A1 (https=)
EP (1) EP3788078A4 (https=)
JP (2) JP2021523117A (https=)
KR (1) KR20210005245A (https=)
CN (1) CN112384535A (https=)
AU (1) AU2019262167A1 (https=)
BR (1) BR112020022236A2 (https=)
CA (1) CA3099338A1 (https=)
MX (1) MX2020011377A (https=)
SG (1) SG11202010911WA (https=)
WO (1) WO2019213468A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200016232A (ko) 2017-05-05 2020-02-14 알라코스 인크. 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물
JP2023541217A (ja) * 2020-07-10 2023-09-29 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 抗ＩｇＥ改変抗体及びその適用
KR102803012B1 (ko) * 2022-08-11 2025-04-30 오씨아이 주식회사 석유계 고연화점 피치의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201603127WA (en) * 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
KR102311761B1 (ko) * 2013-12-09 2021-10-13 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
CA2939931C (en) * 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis

Also Published As

Publication number Publication date
MX2020011377A (es) 2020-11-24
JP2021523117A (ja) 2021-09-02
CN112384535A (zh) 2021-02-19
EP3788078A1 (en) 2021-03-10
BR112020022236A2 (pt) 2021-02-02
KR20210005245A (ko) 2021-01-13
US20210246205A1 (en) 2021-08-12
WO2019213468A1 (en) 2019-11-07
JP2024045612A (ja) 2024-04-02
EP3788078A4 (en) 2022-03-02
AU2019262167A1 (en) 2020-12-10
SG11202010911WA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
AU2020204016A1 (en) Anti-Siglec-8 antibodies and methods of use thereof
CA3062430A1 (en) Methods and compositions for treating inflammatory gastrointestinal disorders
AU2016342036B2 (en) Methods and compositions for treating systemic mastocytosis
CA3130072A1 (en) Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
US20240084005A1 (en) Anti-siglec-6 antibodies and methods of use thereof
US20220162307A1 (en) Methods and compositions for treating allergic ocular diseases
JP2024045612A (ja) 慢性蕁麻疹を処置するための方法および組成物
US20220257758A1 (en) Methods of administering anti-siglec-8 antibodies and corticosteroids
US20190338027A1 (en) Methods and compositions for treating chronic obstructive pulmonary disorder
US20230406920A1 (en) Anti-siglec-8 antibody formulations
US20220380460A1 (en) Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
WO2024043940A1 (en) Methods and compositions for treating atopic dermatitis
EA045206B1 (ru) Способы и композиции для лечения аллергических заболеваний глаз

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251021

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251222